CSS
AVNR

Cubist Systematic Strategies’s AVANIR PHARMACEUTICALS, INC CL A AVNR Stock Holding History

Cubist Systematic Strategies’s Portfolio AVNR Stock Details AVNR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-3,806
Closed -$45K – 2222
2014
Q3 		$45K Sell
3,806
-23,540
-86% -$161K ﹤0.01% 1642
2014
Q2 		$154K Buy
+27,346
New +$126K 0.01% 1244

Other funds holding AVNR

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
WIC
Water Island Capital New York $896M AUM 107.59% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
OAM
Oxford Asset Management Oxford, United Kingdom $232M AUM 31% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Cubist Systematic Strategies's AVNR Position: Q4 2014 in Review

Cubist Systematic Strategies sold out of AVANIR PHARMACEUTICALS, INC CL A (AVNR) in Q4 2014, closing a stake of 3,806 shares — an estimated $45K sold.

Cubist Systematic Strategies first reported a position in AVNR in Q2 2014 and held it in 2 quarters. The position peaked at $154K in Q2 2014. 166 funds tracked by Wall St. Rank hold AVNR as of Q4 2014.

  • Cubist Systematic Strategies reported no remaining AVANIR PHARMACEUTICALS, INC CL A position as of Q4 2014 after selling out during the quarter.
  • Cubist Systematic Strategies sold 3,806 AVANIR PHARMACEUTICALS, INC CL A shares in Q4 2014, an estimated $45K.
  • Cubist Systematic Strategies first reported a position in AVANIR PHARMACEUTICALS, INC CL A in Q2 2014 and held it in 2 quarters.
  • Cubist Systematic Strategies's AVANIR PHARMACEUTICALS, INC CL A position peaked at $154K in Q2 2014.
  • 166 funds tracked by Wall St. Rank held AVANIR PHARMACEUTICALS, INC CL A as of Q4 2014.

Based on Cubist Systematic Strategies's 13F filing for Q4 2014, filed 17 Feb 2015.